Table 1.
Baseline characteristics for participants receiving vehicle–placebo, vehicle–finasteride, TE–placebo, and TE–finasteride
| Variable | Vehicle–placebo | Vehicle–finasteride | TE–placebo | TE–finasteride |
|---|---|---|---|---|
| Age, years | 70.8±9.7 | 69.5±9.2 | 69.2±8.0 | 64.2±4.8 |
| BMI, kg/m2 | 30.4±3.4 | 28.8±3.9 | 29.4±4.6 | 31.1±2.5 |
| Testosterone, ng/dL | 264±92 | 240±110 | 245±73 | 242±147 |
| BioT, ng/dL | 46±22 | 41±17 | 46±17 | 44±20 |
| E2, pg/mL | 12.7±9.5 | 13.6±7.4 | 25.8±34.4 | 26.0±30.2 |
| BioE2, pg/mL | 4.7±3.1 | 4.7±2.1 | 11.0±17.2 | 9.8±9.2 |
| DHT, ng/dL | 25.2±15.1 | 18.9±12.7 | 21.4±6.3 | 21.9±22.4 |
Note: Values are means ± standard deviation.
Abbreviations: BioE2, bioavailable estradiol; BioT, bioavailable testosterone; BMI, body mass index; DHT, dihydrotestosterone; E2, estradiol; TE, testosterone enanthate.